登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301207 证券简称：华兰疫苗公告编号：2025-022 华兰生物疫苗股份有限公司 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 华兰生物疫苗股份有限公司（以下简称"公司"）已于2025年3月29日在《证券时报》、《中国证券 报》、《上海证券报》及巨潮资讯网（www.cninfo.com.cn）披露了《关于召开2024年度股东大会的通 知》（公告编号：2025-020）。本次股东大会采取现场投票和网络投票相结合的表决方式召开，根据有 关规定，现将股东大会的相关事项再次提示如下： 一、召开会议的基本情况 1、股东大会届次：2024年度股东大会； 2、股东大会召集人：公司董事会； 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行政法规、部门规章、规范性 文件和公司章程的规定。 4、会议召开方式：现场投票+网络投票 （1）现场投票：股东本人出席现场会议或者通过授权委托书（附件二）委托他人出席现场会议； （2）网络投票：本次股东大会通过深圳证券交 ...

Core Viewpoint - The company reported a revenue of 2.178 billion yuan for FY2024, a year-on-year increase of 12%, but a net profit attributable to shareholders of 190 million yuan, a decrease of 58% compared to the previous year [1] - For Q1 2025, the company achieved a revenue of 687 million yuan, a year-on-year increase of 37%, with a net profit attributable to shareholders of 51 million yuan, down 41% year-on-year [1] Group 1: Financial Performance - FY2024 revenue from the amino acids and vitamins segment was 1.5 billion yuan and 200 million yuan respectively, with year-on-year changes of +3% and -5% [1] - The gross profit margin for amino acids was 30%, down 13.3 percentage points year-on-year, while for vitamins it was 21%, down 34.3 percentage points year-on-year [1] - The sales volume of amino acids reached 97,123 tons, a year-on-year increase of 26%, which was the main reason for revenue growth [1] Group 2: Market Dynamics - The price of valine has been under pressure, with a current price of 15 yuan/kg, a 10% increase quarter-on-quarter, but still at a low level [1] - The price spread has expanded to 9,218 yuan/ton, a 22% increase quarter-on-quarter [1] - The potential rise in domestic soybean prices due to escalating China-US tariff tensions may accelerate the reduction of soybean meal, which could benefit valine prices in the medium to long term [1] Group 3: Product Development - The company is increasing investment in new product development, achieving breakthroughs in 1,3-propanediol (PDO), succinic acid, tryptophan, and arginine [2] - The company’s PDO project is expected to benefit from accelerated domestic substitution due to trade tensions, as DuPont is a major manufacturer of PDO [2] - Future projects include the establishment of production facilities for various amino acids, which will enhance product structure and market competitiveness [2] Group 4: Investment Outlook - The company is projected to achieve net profits attributable to shareholders of 290 million yuan, 460 million yuan, and 530 million yuan for the years 2025 to 2027 respectively [3] - The company has received a "recommended" rating for its investment potential [4]

4月22日晚间，特宝生物（688278.SH）交出了2025年第一季度报告。 对于净利润增长原因，特宝生物称，重点产品派格宾销售收入快速增长；同时总体费用率降低，盈利水 平提高。 报告显示，特宝生物第一季度营业收入为6.73亿元，同比增长23.48%；归母净利润为1.82亿元，同比增 长41.40%。 多家券商在近日发布的研报中表示看好派格宾带来的业绩增长。如财信证券称，派格宾新增适应症及长 效生长激素获批在即，有望助力特宝生物业绩保持快速增长。 （文章来源：21世纪经济报道） 然而市场却并未买账，4月23日开盘，特宝生物股价低开低走，盘中一度跌超10%。 有投资者指出，特宝生物扣非净利润增速正在变慢，还有投资者认为业绩增速不及预期。 财务数据显示，特宝生物今年一季度扣非净利润为1.89亿元，去年同期为1.46亿元，同比增长28.81%， 而去年同期的增长率为42.90%。 南财快讯记者以投资者身份致电特宝生物，工作人员表示，不太了解投资者所讲的预期是基于哪种情况 做的测算。今年一季度和去年一季度对比，需要考虑集采价格的影响。江西集采从2024年5月中下旬开 始陆续执行，到今年一季度大部分地区都按照集采价格销 ...

Core Insights - The article emphasizes the improvement of factors affecting the payment for innovative drugs, highlighting the government's commitment to supporting the development of innovative drugs through the establishment of a catalog for innovative drugs in the 2025 government work report [2][8][25]. Industry Overview - The innovative drug payment structure in China is primarily reliant on basic medical insurance and out-of-pocket payments from patients, with the market size expected to reach 162 billion yuan in 2024 [8][10]. - The government has introduced a "Class C catalog" for innovative drugs, which aims to include high-value drugs that cannot be covered by basic medical insurance, thereby promoting commercial health insurance's contribution to innovative drug payments [9][25]. Investment Dynamics - In Q1 2025, the biopharmaceutical sector in China saw 57 financing cases totaling 5.772 billion yuan, indicating a slight decrease in activity compared to previous quarters [22][24]. - Chemical pharmaceuticals attracted the most investment, with 25 cases amounting to 3.143 billion yuan, while the focus areas included small molecule drugs, antibody drugs, and cell therapies [22][23]. - Early-stage financing cases decreased from 59.38% in Q4 2024 to 54.39% in Q1 2025, while mid-to-late stage financing cases increased, reflecting a shift in investor sentiment towards more mature projects [23][32]. Key Financing Events - Notable financing events in Q1 2025 included: - Yingxi Intelligent's completion of a $110 million E-round financing [13]. - Li Bang Pharmaceutical's successful C-round financing of 550 million yuan [15]. - A strategic investment of 600 million yuan in the Huizhou Traditional Chinese Medicine Group [14] [38]. Policy Environment - The government has reiterated its support for innovative drugs in the 2025 work report, signaling a stable policy environment for biopharmaceutical companies [24][32]. - Various policies have been introduced to enhance the quality and development of traditional Chinese medicine, including streamlined approval processes and increased market accessibility for innovative traditional Chinese medicines [40][46]. Trends in Traditional Chinese Medicine - The development of new traditional Chinese medicines is gaining momentum, with a significant increase in clinical trial applications, reflecting a growing interest in integrating traditional practices with modern scientific methods [40][42]. - The approval process for traditional Chinese medicines has been expedited, with 11 new traditional Chinese medicines added to the insurance catalog in 2024, enhancing their market reach [40][46].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:002880 证券简称:卫光生物 公告编号:2025-008 深圳市卫光生物制品股份有限公司 关于2024年度日常关联交易执行情况及 预计2025年度日常关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、日常关联交易基本情况 （一）日常关联交易概述 深圳市卫光生物制品股份有限公司（以下简称公司）于2025年4月21日召开第三届董事会第三十二次会 议、第三届监事会第二十五次会议审议通过了《关于2024年度日常关联交易执行情况及预计2025年度日 常关联交易的议案》。 公司及子公司基于实际经营需要，预计2025年与关联方武汉生物制品研究所有限责任公司发生日常关联 交易的金额为100万元，公司2024年实际发生的日常关联交易金额为2.88万元。 根据《深圳证券交易所股票上市规则》《公司章程》等的相关规定，本事项无需提交公司股东大会审 议。 （二）2024年度日常关联交易执行情况 ■ （三）预计2025年度日常关联交易情况 ■ 二、关联方及关联关系 公司名称：武汉生物制品研究所有限责任公司 ...

华恒生物公告，2024年度实现营业总收入21.78亿元，同比增加12.37%；归属于母公司所有者的净利润 1.9亿元，同比减少57.80%。公司拟向全体股东每10股派发现金红利2.5元(含税)，合计拟派发现金红利 6230.68万元(含税)，占公司2024年度合并报表归属于上市公司股东净利润的比例为32.88%。 ...

卫光生物（002880）公告，2024年营业收入12.03亿元，同比增长14.75%。归属于上市公司股东的净利 润2.54亿元，同比增长15.95%。基本每股收益1.12元/股，同比增长15.94%。公司拟向全体股东每10股派 发现金红利2元(含税)，送红股0股(含税)，不以公积金转增股本。 ...

卫光生物（002880）公告，2025年第一季度营业收入2.25亿元，同比下降0.57%。净利润4376.82万元， 同比下降6.54%。 ...

特宝生物公告，2025年第一季度营收为6.73亿元，同比增长23.48%；净利润为1.82亿元，同比增长 41.40%。 ...

Investment Rating - The investment rating for the company is upgraded to "Buy" [1] Core Views - The company experienced a steady growth in its conventional business, but increased investments have put pressure on profit margins [4] - In 2024, the company achieved a revenue of 614 million yuan, a year-on-year decrease of 5.06%, while the net profit attributable to the parent company was 122 million yuan, down 53.13% year-on-year [4] - The conventional business generated a revenue of 533 million yuan in 2024, reflecting a year-on-year growth of 10.54% [4] - The company has adjusted its profit forecasts for 2025-2026 and added a new forecast for 2027, expecting net profits of 156 million, 183 million, and 209 million yuan respectively [4] Financial Summary - In 2024, the company’s revenue from the recombinant protein business was 273 million yuan, up 6.87% year-on-year, while the antibody business revenue fell to 106 million yuan, down 41.20% [5] - The CRO service business generated a revenue of 169 million yuan, marking a year-on-year increase of 9.40% [5] - The company’s overseas revenue reached 354 million yuan in 2024, accounting for 57.74% of total revenue [6] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.28, 1.50, and 1.72 yuan respectively, with corresponding P/E ratios of 47.4, 40.4, and 35.3 times [4][8]